Cite
HARVARD Citation
Li, M. et al. (2022). Secukinumab for PASS syndrome: A new choice for therapeutic challenge?. Dermatologic therapy. 35 (7), p. n/a. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Li, M. et al. (2022). Secukinumab for PASS syndrome: A new choice for therapeutic challenge?. Dermatologic therapy. 35 (7), p. n/a. [Online].